Oncology
Latest news
826 articles · 20 / page
Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC
A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate
Preoperative Total Diet Replacement Safely Reduces Morbidity Risk and Preserves Muscle Mass in Colorectal Cancer Surgery
The CARE feasibility trial demonstrates that a preoperative low-energy total diet replacement program is safe and effective for colorectal cancer patients with excess weight. Significant weight loss was achieved without compromising lean mu
Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer
A prospective cohort study demonstrates that a structured shared decision-making (SOP) model significantly increases the utilization of multidisciplinary palliative care services for patients with stage IV oral cavity cancer, bridging the g
Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome
This article explores a landmark mixed-methods study establishing a digital biomarker ontology for the early detection of Cytokine Release Syndrome (CRS). By identifying core physiological markers, researchers aim to transform immunotherapy
Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial
A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a
Streamlining Sarcoma Care: Five-Day Preoperative Radiation Matches Long-Term Efficacy of 5-Week Regimens
A Phase 2 clinical trial reveals that an ultrahypofractionated 5-day preoperative radiation regimen for high-risk soft tissue sarcoma provides durable local control and favorable late-term toxicity compared to the conventional 5-week course
AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care
The 2025 Advanced Urologic Cancer Consensus Conference (AUC3) issues practical, evidence‑informed expert recommendations on diagnosis, perioperative therapy, frontline and later‑line systemic sequencing, and special populations for RCC and
MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment
The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep
Fixed-Duration Therapy Challenging the Continuous Paradigm in Chronic Lymphocytic Leukemia: Insights from the CLL17 Trial
The Phase 3 CLL17 trial demonstrates that fixed-duration venetoclax-based regimens are noninferior to continuous ibrutinib in previously untreated CLL, offering deep molecular responses and comparable progression-free survival while allowin
Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia
Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patien
Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high ra
Trastuzumab Deruxtecan Redefines Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer: Insights from DESTINY-Breast05
The DESTINY-Breast05 trial demonstrates that Trastuzumab Deruxtecan significantly improves invasive disease-free survival compared to Trastuzumab Emtansine in patients with residual HER2-positive early breast cancer, establishing a new pote
Disitamab Vedotin Plus Gemcitabine Shows Promise as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer
A phase 2 trial reports notable pCR rates and manageable toxicity for Disitamab Vedotin plus gemcitabine in HER2-positive MIBC patients.
Tailoring Systemic Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Evidence by Disease Volume and Timing of Metastasis
A living network meta-analysis refines treatment strategies for mHSPC subgroups, favoring triplet therapy in synchronous high-volume cases and ARPI doublet therapy in others.
Refining Prostate Cancer Risk Prediction in Men of African Ancestry: Integrating Pathogenic Variants, Polygenic Scores, and Family History
This study identifies key germline variants and demonstrates how combining genetic data with family history improves personalized prostate cancer risk assessment in men of African ancestry, guiding future screening strategies.
Personalizing Breast Cancer Screening: Insights from the WISDOM Trial on Risk-Based vs Annual Mammography
The WISDOM trial shows risk-based breast cancer screening using genetic and clinical data as a safe alternative to annual mammography, tailoring screening frequency by individual risk without increasing advanced cancer rates.
Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status
A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.
Broad Genetic Testing Reveals Hidden Breast Cancer Risk in Women Without Family History
The WISDOM trial found that 3.1% of women without breast cancer carried pathogenic variants in key susceptibility genes, many outside existing testing guidelines.
Simple vs Radical Hysterectomy: Balancing Survival Outcomes and Quality of Life in Early Cervical Cancer
Evidence suggests simple hysterectomy with pelvic lymphadenectomy may offer similar survival outcomes to radical hysterectomy in early-stage cervical cancer, with fewer adverse events and better short-term quality of life.
Breast Surgery in Metastatic Breast Cancer: Local Control Without Survival Benefit
Randomised trials show breast surgery improves local disease control but not overall survival in de novo metastatic breast cancer.
Browse by specialty
Open language-specific specialty feeds and department pages.